# OnKure Therapeutics, Inc.: financial statements, quarterly

OKUR · Nasdaq · CIK 1637715 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/okur.md) · [Financials](/companies/okur/financials.md) · [Filings](/companies/okur/filings.md) · [Insiders](/companies/okur/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/okur/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [13.6](/filings/0000950170-24-123233.md) | [(6.9) d](/filings/0000950170-25-036252.md) | [8.6](/filings/0000950170-25-063970.md) | [10.8](/filings/0001193125-25-178981.md) | [10.1](/filings/0001193125-25-269540.md) | [14.4 d](/filings/0001193125-26-104147.md) | [13.0](/filings/0001193125-26-206345.md) | [12.6](/filings/0001193125-26-332773.md) | [11.9](/filings/0001193125-25-269540.md) | [10.7 d](/filings/0001193125-26-104147.md) | [11.7](/filings/0001193125-26-206345.md) | [12.6](/filings/0001193125-26-332773.md) |
| Operating income | $m | [(20.9)](/filings/0000950170-24-123233.md) | [21.1 d](/filings/0000950170-25-036252.md) | [(9.8)](/filings/0000950170-25-063970.md) | [(14.3)](/filings/0001193125-25-178981.md) | [(11.5)](/filings/0001193125-25-269540.md) | [(18.7) d](/filings/0001193125-26-104147.md) | [(17.0)](/filings/0001193125-26-206345.md) | [(16.3)](/filings/0001193125-26-332773.md) | [(15.5)](/filings/0001193125-25-269540.md) | [(14.1) d](/filings/0001193125-26-104147.md) | [(15.6)](/filings/0001193125-26-206345.md) | [(16.9)](/filings/0001193125-26-332773.md) |
| Net income | $m | [(19.2)](/filings/0000950170-24-123233.md) | [18.5 d](/filings/0000950170-25-036252.md) | [(9.5)](/filings/0001193125-25-269540.md) | [(14.1)](/filings/0001193125-25-269540.md) | [(11.6)](/filings/0001193125-25-269540.md) | [(17.4)](/filings/0001193125-25-269540.md) | [(15.9)](/filings/0001193125-26-332773.md) | [(15.4)](/filings/0001193125-26-332773.md) | [(14.7)](/filings/0001193125-26-332773.md) | [(13.5)](/filings/0001193125-26-332773.md) | [(15.2)](/filings/0001193125-26-332773.md) | [(15.3)](/filings/0001193125-26-332773.md) |
| Diluted EPS | $ per share | [(5.68)](/filings/0000950170-24-123233.md) | not reported | [(30.37)](/filings/0000950170-25-063970.md) | [(44.82)](/filings/0001193125-25-178981.md) | [(36.55)](/filings/0001193125-25-269540.md) | not reported | [(1.19)](/filings/0001193125-26-206345.md) | [(1.14)](/filings/0001193125-26-332773.md) | [(1.09)](/filings/0001193125-25-269540.md) | not reported | [(1.11)](/filings/0001193125-26-206345.md) | [(0.31)](/filings/0001193125-26-332773.md) |
| Basic EPS | $ per share | [(5.68)](/filings/0000950170-24-123233.md) | not reported | [(30.37)](/filings/0000950170-25-063970.md) | [(44.82)](/filings/0001193125-25-178981.md) | [(36.55)](/filings/0001193125-25-269540.md) | not reported | [(1.19)](/filings/0001193125-26-206345.md) | [(1.14)](/filings/0001193125-26-332773.md) | [(1.09)](/filings/0001193125-25-269540.md) | not reported | [(1.11)](/filings/0001193125-26-206345.md) | [(0.31)](/filings/0001193125-26-332773.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [11.7](/filings/0000950170-23-062910.md) | [29.9](/filings/0000950170-25-036252.md) | [20.4](/filings/0000950170-24-054452.md) | [36.0](/filings/0000950170-24-096411.md) | [60.7](/filings/0000950170-24-123233.md) | [111](/filings/0001193125-26-104147.md) | [96.7](/filings/0000950170-25-063970.md) | [83.4](/filings/0001193125-25-178981.md) | [70.3](/filings/0001193125-25-269540.md) | [59.1](/filings/0001193125-26-332773.md) | [192](/filings/0001193125-26-206345.md) | [167](/filings/0001193125-26-332773.md) |
| Current assets | $m | [129](/filings/0000950170-23-062910.md) | [33.8](/filings/0000950170-25-036252.md) | [83.9](/filings/0000950170-24-054452.md) | [78.0](/filings/0000950170-24-096411.md) | [77.0](/filings/0000950170-24-123233.md) | [113](/filings/0001193125-26-104147.md) | [98.2](/filings/0000950170-25-063970.md) | [84.6](/filings/0001193125-25-178981.md) | [71.5](/filings/0001193125-25-269540.md) | [60.8](/filings/0001193125-26-332773.md) | [197](/filings/0001193125-26-206345.md) | [178](/filings/0001193125-26-332773.md) |
| Total assets | $m | [130](/filings/0000950170-23-062910.md) | [35.7](/filings/0000950170-25-036252.md) | [84.6](/filings/0000950170-24-054452.md) | [78.7](/filings/0000950170-24-096411.md) | [77.6](/filings/0000950170-24-123233.md) | [115](/filings/0001193125-26-104147.md) | [99.9](/filings/0000950170-25-063970.md) | [86.1](/filings/0001193125-25-178981.md) | [72.8](/filings/0001193125-25-269540.md) | [62.1](/filings/0001193125-26-332773.md) | [199](/filings/0001193125-26-206345.md) | [179](/filings/0001193125-26-332773.md) |
| Current liabilities | $m | [13.6](/filings/0000950170-23-062910.md) | [7.3](/filings/0000950170-25-036252.md) | [2.8](/filings/0000950170-24-054452.md) | [1.3](/filings/0000950170-24-096411.md) | [3.2](/filings/0000950170-24-123233.md) | [10.5](/filings/0001193125-26-104147.md) | [8.8](/filings/0000950170-25-063970.md) | [7.6](/filings/0001193125-25-178981.md) | [6.2](/filings/0001193125-25-269540.md) | [5.9](/filings/0001193125-26-332773.md) | [14.3](/filings/0001193125-26-206345.md) | [6.6](/filings/0001193125-26-332773.md) |
| Total liabilities | $m | [15.4](/filings/0000950170-23-062910.md) | [7.8](/filings/0000950170-25-036252.md) | [3.4](/filings/0000950170-24-054452.md) | [1.8](/filings/0000950170-24-096411.md) | [3.6](/filings/0000950170-24-123233.md) | [11.1](/filings/0001193125-26-104147.md) | [9.2](/filings/0000950170-25-063970.md) | [7.9](/filings/0001193125-25-178981.md) | [6.4](/filings/0001193125-25-269540.md) | [5.9](/filings/0001193125-26-332773.md) | [14.3](/filings/0001193125-26-206345.md) | [7.2](/filings/0001193125-26-332773.md) |
| Shareholders' equity | $m | [115](/filings/0000950170-24-123233.md) | [(102)](/filings/0001193125-26-104147.md) | [(111)](/filings/0001193125-25-269540.md) | [(124)](/filings/0001193125-25-269540.md) | [(135)](/filings/0001193125-25-269540.md) | [104](/filings/0001193125-26-332773.md) | [90.6](/filings/0001193125-26-332773.md) | [78.2](/filings/0001193125-26-332773.md) | [66.4](/filings/0001193125-26-332773.md) | [56.2](/filings/0001193125-26-332773.md) | [184](/filings/0001193125-26-332773.md) | [172](/filings/0001193125-26-332773.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(18.8) d](/filings/0000950170-24-123233.md) | [9.4 d](/filings/0000950170-25-036252.md) | [(10.6)](/filings/0000950170-25-063970.md) | [(6.5) d](/filings/0001193125-25-178981.md) | [(10.7) d](/filings/0001193125-25-269540.md) | [(23.4) d](/filings/0001193125-26-104147.md) | [(14.0)](/filings/0001193125-26-206345.md) | [(13.3) d](/filings/0001193125-26-332773.md) | [(13.0) d](/filings/0001193125-25-269540.md) | [(11.5) d](/filings/0001193125-26-104147.md) | [(12.9)](/filings/0001193125-26-206345.md) | [(10.4) d](/filings/0001193125-26-332773.md) |
| Capital expenditure | $m | [0.0 d](/filings/0000950170-24-123233.md) | [0.1 d](/filings/0000950170-25-036252.md) | [0.0](/filings/0000950170-25-063970.md) | [0.0 d](/filings/0001193125-25-178981.md) | [0.0 d](/filings/0001193125-25-269540.md) | [0.0 d](/filings/0001193125-26-104147.md) | [0.0](/filings/0001193125-26-206345.md) | [0.0 d](/filings/0001193125-26-332773.md) | [0.0 d](/filings/0001193125-25-269540.md) | [0.0 d](/filings/0001193125-26-104147.md) | [0.0](/filings/0001193125-26-206345.md) | [0.0 d](/filings/0001193125-26-332773.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [24.5](/filings/0000950170-23-062910.md) | [25.0](/filings/0000950170-24-054452.md) | [30.2](/filings/0000950170-24-096411.md) | [3.4](/filings/0000950170-24-123233.md) | [0.3](/filings/0000950170-25-063970.md) | [0.3](/filings/0001193125-25-178981.md) | [0.3](/filings/0001193125-25-269540.md) | [13.4](/filings/0001193125-26-206345.md) | [13.5](/filings/0001193125-26-332773.md) | [13.5](/filings/0001193125-25-269540.md) | [13.7](/filings/0001193125-26-206345.md) | [49.9](/filings/0001193125-26-332773.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 40,496,309 at 2026-08-03, from the cover of the [10-Q filed 2026-08-04](/filings/0001193125-26-332773.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.